Author Search

```
=> FILE CAPLUS
FILE 'CAPLUS' ENTERED AT 14:33:53 ON 29 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 Mar 2007  VOL 146 ISS 14
FILE LAST UPDATED: 28 Mar 2007  (20070328/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> D QUE L16
L14         173 SEA FILE=CAPLUS ABB=ON  PLU=ON  MORLEY A?/AU
L15          35 SEA FILE=CAPLUS ABB=ON  PLU=ON  POYSER J?/AU
L16           4 SEA FILE=CAPLUS ABB=ON  PLU=ON  L14 AND L15


=> D IBIB ED ABS 1-4

L16  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2005:1004735  CAPLUS  Full-text
DOCUMENT NUMBER:          143:306312
TITLE:                    Preparation of hydantoin derivatives for use as tace
                          and aggrecanase inhibitors
INVENTOR(S):              Burrows, Jeremy Nicholas; Morley, Andrew David
                          ; Tucker, Howard; Poyser, Jeffrey Philip
PATENT ASSIGNEE(S):       Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE:                   PCT Int. Appl., 91 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    -------------------      --------
     WO 2005085232         A1    20050915    WO 2005-GB759            20050301
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
```

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2004-5101 A 20040306
OTHER SOURCE(S): MARPAT 143:306312
ED Entered STN: 16 Sep 2005
GI



I

AB Title compds. I [Y1-2 = O, S; Z = (un)substituted amino, amido, etc.; n = 0-2; m = 1-4; p = 0-2; q = 0-1; A = arylene, heteroarylene, heterocyclylene; X = absent, O, SO0-2, (un)substituted amino, etc.; B = aryl, heteroaryl, carbocyclyl, etc.; R1, R1a, R1b, R1c = H, alkyl, cycloalkyl; R2 = H, halo, heterocyclyl, alkoxy, etc.; R3-6 = H, alk(en/yn)yl, cycloalkyl, etc.] are prepared For instance, 5-[[3-Methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxoazetidin-1- yl]methyl]imidazolidine-2,4-dione (II) is prepared in 9 steps from Me 2-[4-(benzyloxy)phenyl]propanoate, 2,2-dimethyl-1,3-dioxolane-4- methaneamine and 4-chloro-2-methylquinoline. I are useful in the inhibition of metalloproteinases and in particular in the inhibition of TNF-α converting enzyme (TACE), aggrecanase or the combination thereof; II caused 50% inhibition of TACE at 44 nM. I are useful in the treatment of inflammatory and autoimmune diseases.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:606462 CAPLUS Full-text
DOCUMENT NUMBER: 141:157027
TITLE: Preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment of inflammatory diseases.
INVENTOR(S): Faull, Alan Wellington; Johnstone, Craig; **Morley, Andrew David; Poyser, Jeffrey Philip**
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063186	A1	20040729	WO 2004-GB96	20040113

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ

EP 1583755	A1	20051012	EP 2004-701627	20040113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006516273	T	20060629	JP 2006-500200	20040113
US 2006058522	A1	20060316	US 2005-542326	20050713
PRIORITY APPLN. INFO.:			SE 2003-92 A	20030115
			WO 2004-GB96 W	20040113

OTHER SOURCE(S): MARPAT 141:157027
ED Entered STN: 29 Jul 2004
GI



AB Title compds. I [R1 = H, CH3; R2 = H, halo, CN, etc.; R3, R4 = H, CH3; A = 6-membered aromatic ring optionally incorporating one or two nitrogen atoms; X = NR6; R5 = H, Cl, alkyl, etc.; R6 = H, Cl, alkyl] and their pharmaceutically acceptable salts were prepared For example, Pd mediated coupling of 2-[(aminocarbonyl)amino]-5-bromothiophene-3-carboxamide and bromide II, e.g., prepared from 4-bromobenzylbromide and 2,2,2-trifluoroethylamine, afforded thiophenylcarboxamide III. In IKK-2 filter kinase inhibition assays, 4-examples of compds. I exhibited IC50 values ranging from 0.00056-0.066 μM, e.g., the IC50 value of thiophenylcarboxamide III was 0.0036 μM. Compds. I are claimed useful for the treatment of inflammatory diseases.

L16 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2004:606461 CAPLUS Full-text
DOCUMENT NUMBER:	141:157026
TITLE:	Preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment of inflammatory diseases.
INVENTOR(S):	**Morley, Andrew David; Poyser, Jeffrey Philip**
PATENT ASSIGNEE(S):	Astrazeneca Ab, Swed.; Astrazeneca UK Limited
SOURCE:	PCT Int. Appl., 46 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063185	A1	20040729	WO 2004-GB106	20040113
WO 2004063185	A8	20040923		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004203967	A1	20040729	AU 2004-203967	20040113
CA 2512336	A1	20040729	CA 2004-2512336	20040113
EP 1583756	A1	20051012	EP 2004-701632	20040113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006774	A	20051227	BR 2004-6774	20040113
CN 1738812	A	20060222	CN 2004-80002304	20040113
JP 2006515355	T	20060525	JP 2006-500206	20040113
US 2006111431	A1	20060525	US 2005-542044	20050713
NO 2005003810	A	20051012	NO 2005-3810	20050812
PRIORITY APPLN. INFO.:			SE 2003-91 A	20030115
			WO 2004-GB106 A	20040113

OTHER SOURCE(S): MARPAT 141:157026
ED Entered STN: 29 Jul 2004
GI



I



II



III

AB Title compds. I [R1 = H, CH3; R2 = H, halo, CN, etc.; X = C(R4R5)yNR3(CR4R5)m-Ar; y = n + 1; n = 1-3; m = 0-3; R3 = H, (un)substitued alkenyl, alkyl; R4, R5 = H, alkyl with provisos; Ar = Ph ring or a 5- or 6- membered heterocyclic ring containing one to three heteroatoms, e.g., O, N, S;] and their pharmaceutically acceptable salts were prepared For example, Pd mediated coupling of 2-[(aminocarbonyl)amino]- 5-bromothiophene-3-carboxamide and bromide II, e.g., prepared from 1-bromo-2-[2-chloroethoxy]benzene and N-methylbenzylamine, afforded thiophenylcarboxamide III. In IKK-2 filter kinase inhibition assays, 6-examples of compds. I exhibited IC50 values ranging from 0.01-1.43 μM, e.g., the IC50 value of thiophenylcarboxamide III was 0.04 μM. Compds. I are claimed useful for the treatment of inflammatory diseases.

L16 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:97411 CAPLUS Full-text
DOCUMENT NUMBER: 138:137162
TITLE: Preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase
INVENTOR(S): Faull, Alan; Johnstone, Craig; **Morley, Andrew**; **Poyser, Jeffrey Philip**
PATENT ASSIGNEE(S): Astrazeneca A.B., Swed.
SOURCE: PCT Int. Appl., 180 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003010158	A1	20030206	WO 2002-SE1403	20020719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2454703	A1	20030206	CA 2002-2454703	20020719
EP 1421074	A1	20040526	EP 2002-751935	20020719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011473	A	20041026	BR 2002-11473	20020719
CN 1541214	A	20041027	CN 2002-815836	20020719
JP 2005503372	T	20050203	JP 2003-515517	20020719
NZ 530750	A	20050826	NZ 2002-530750	20020719
US 2004242573	A1	20041202	US 2004-484569	20040122
US 7125896	B2	20061024		
ZA 2004000492	A	20050422	ZA 2004-492	20040122
NO 2004000313	A	20040325	NO 2004-313	20040123
HK 1071129	A1	20061229	HK 2005-103629	20050427
US 2007015819	A1	20070118	US 2006-516225	20060906
PRIORITY APPLN. INFO.:			SE 2001-2616 A	20010725
			WO 2002-SE1403 W	20020719
			US 2004-484569 A3	20040122

OTHER SOURCE(S): MARPAT 138:137162
ED Entered STN: 07 Feb 2003
GI



I



II

AB Title compds. I [R1 = NH2, (un)substituted methyl; X = O, S; R2 = H, halo, CN, NO2, amino, carboxamido, carboxy, etc.; A = Ph, 5-7-membered (un)substituted heteroarom. ring; n = 1-2; R3 = W-Y-Z; W = O, SO0-2; amino, CH2(O), bond; Y = (CH2)0-2-T-(CH2)0-2; T = O, CO, alkyl; Z = Ph, 5-6-membered (un)substituted heteroarom. ring, etc.; with specific exceptions] are prepared For instance, (1,1'-biphenyl-4-yl)acetone, cyanoacetamide, sulfur and morpholine in EtOH at 55° are reacted to give 2-Amino-4-methyl-5-(1,1'-biphenyl-4-yl)-3-thiophencarboxamide. This intermediate is treated with trichloroacetyl isocyanate and ammonia in MeOH to give example compound II. Compds. of the invention have IC50 < 10 μM for IKK2 kinase. I are useful for the treatment of inflammatory diseases.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Structure Search

```
=> D QUE L6
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation:
Uploading L1-III.str
```




```
chain nodes :
1  11  12  13  14  15  16  17  20
ring nodes :
2  3  4  5  6  7
ring/chain nodes :
8  9  10  19
chain bonds :
1-2  1-11  1-15  8-20  11-12  12-13  12-14  15-17  15-16
ring/chain bonds :
8-9  9-10  10-19
ring bonds :
2-3  2-7  3-4  4-5  5-6  6-7
exact/norm bonds :
1-2  1-11  1-15  8-9  8-20  9-10  10-19  11-12  12-13  12-14  15-17  15-16
```

```
normalized bonds :
2-3  2-7  3-4  4-5  5-6  6-7


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  19:CLASS
20:CLASS  21:Atom

Generic attributes :
1:
Saturation              : Unsaturated
Type of Ring System     : Monocyclic

Element Count :
Node 1: Limited
    C,C4
    S,S1




L3            80 SEA FILE=REGISTRY SSS FUL L1
L4             4 SEA FILE=CAPLUS ABB=ON  PLU=ON  L3
L5             4 SEA FILE=CAPLUS ABB=ON  PLU=ON  L4 AND PATENT/DT
L6             3 SEA FILE=CAPLUS ABB=ON  PLU=ON  L5 AND (PRY<=2004 OR AY<=2004
                 OR PY<=2004)


=> S L6 NOT L16
L17            1 L6 NOT L16

=> FILE MARPAT
FILE 'MARPAT' ENTERED AT 14:35:09 ON 29 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 146 ISS 12 (20070325/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US   2007032719 08 FEB 2007
DE 102006011317 15 FEB 2007
EP      1750119 07 FEB 2007
JP   2007035357 08 FEB 2007
WO   2007022718 01 MAR 2007
GB      2428675 07 FEB 2007
FR      2889524 09 FEB 2007
RU      2293086 10 FEB 2007
CA      2552059 19 JAN 2007

Expanded G-group definition display now available.

=> D QUE L13
L10             STR
```

Structure attributes must be viewed using STN Express query preparation:
Uploading L1-V.str





chain nodes :
1 8 9 10 11 12 13 14 15 16 17 18 19 24 26 31 36 37
ring nodes :
2 3 4 5 6 7 27 28 29 30 38
chain bonds :
1-2 1-11 1-15 8-9 9-10 10-18 11-12 12-13 12-14 15-17 15-16 18-19 24-26
30-31 36-37 37-38
ring bonds :
2-3 2-7 3-4 4-5 5-6 6-7 27-28 28-29 29-30
exact/norm bonds :
1-2 1-11 1-15 8-9 9-10 10-18 11-12 12-13 12-14 15-17 15-16 18-19 24-26
27-28 28-29 29-30 30-31 37-38
exact bonds :
36-37
normalized bonds :
2-3 2-7 3-4 4-5 5-6 6-7

G1:[*1],[*2],[*3]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:Atom 24:CLASS
25:Atom 26:CLASS 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 36:CLASS 37:CLASS
38:Atom
Generic attributes :
1:
Saturation : Unsaturated
Type of Ring System : Monocyclic
19:

```
Saturation              : Unsaturated
31:
Saturation              : Unsaturated

Element Count :
Node 1: Limited
    C,C4
    S,S1



L12           2 SEA FILE=MARPAT SSS FUL L10
L13           1 SEA FILE=MARPAT ABB=ON  PLU=ON  L12/COM


=> DUP REM L17 L13
FILE 'CAPLUS' ENTERED AT 14:35:44 ON 29 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MARPAT' ENTERED AT 14:35:44 ON 29 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)
PROCESSING COMPLETED FOR L17
PROCESSING COMPLETED FOR L13
L18           2 DUP REM L17 L13 (0 DUPLICATES REMOVED)
                ANSWER '1' FROM FILE CAPLUS
                ANSWER '2' FROM FILE MARPAT

=> D IBIB ED ABS HITSTR 1; D IBIB AB QHIT 2

L18  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2001:597977  CAPLUS  Full-text
DOCUMENT NUMBER:          135:180698
TITLE:                    Preparation of thiophenecarboxamides as inhibitors of
                          the enzyme IKK-2
INVENTOR(S):              Baxter, Andrew; Brough, Stephen; Faull, Alan;
                          Johnstone, Craig; Mcinally, Thomas
PATENT ASSIGNEE(S):       Astrazeneca AB, Swed.
SOURCE:                   PCT Int. Appl., 85 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2001058890         A1    20010816    WO 2001-SE248            20010207 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
```

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2396824	A1	20010816	CA 2001-2396824		20010207 <--
EP 1261600	A1	20021204	EP 2001-902951		20010207 <--
EP 1261600	B1	20040506			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001008143	A	20030121	BR 2001-8143		20010207 <--
JP 2003522766	T	20030729	JP 2001-558440		20010207 <--
AT 266019	T	20040515	AT 2001-902951		20010207 <--
NZ 519947	A	20040528	NZ 2001-519947		20010207 <--
PT 1261600	T	20040831	PT 2001-902951		20010207 <--
ES 2218376	T3	20041116	ES 2001-1902951		20010207 <--
AU 781047	B2	20050505	AU 2001-30705		20010207 <--
US 2002107252	A1	20020808	US 2002-868884		20020205 <--
ZA 2002005300	A	20031002	ZA 2002-5300		20020702 <--
NO 2002003786	A	20020923	NO 2002-3786		20020809 <--
PRIORITY APPLN. INFO.:			GB 2000-3154	A	20000212 <--
			WO 2001-SE248	W	20010207 <--

OTHER SOURCE(S): MARPAT 135:180698
ED Entered STN: 17 Aug 2001
GI



I



II

AB The title compds. [I; A = 5-membered heteroarom. ring containing 1-2 heteroatoms selected from O, N or S; R1 = (un)substituted Ph, 5-7 membered heteroarom. ring containing 1-3 heteroatoms selected from O, N or S; R2 = H, halo, CN, etc.; X = O, S], useful in the treatment or prophylaxis of inflammatory disease, were prepared Thus, refluxing 3-amino-5-phenyl-2-thiophenecarboxamide with trimethylsilyl isocyanate in DMF/CH2Cl2 afforded II.

IT **354811-07-7P 354811-08-8P 354811-11-3P**
354811-12-4P 354811-13-5P 354811-14-6P
354811-15-7P 354811-16-8P 354811-17-9P
354811-18-0P 354811-19-1P 354811-20-4P
354811-23-7P 354811-26-0P 354811-27-1P
354811-51-1P 354811-52-2P 354811-79-3P
354811-80-6P 354811-82-8P 354811-83-9P
354811-84-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)

RN 354811-07-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-[2-(dimethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-08-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[2-(dimethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-11-3 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-12-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-13-5 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-14-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[3-(dimethylamino)propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-15-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-[2-(dimethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-16-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-17-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-18-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-19-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-[3-(dimethylamino)propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-20-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-23-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-26-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-27-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-[3-(dimethylamino)propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-51-1 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-52-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 354811-79-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-80-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-82-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(dimethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-83-9 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-84-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 2 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 141:157026 MARPAT Full-text
TITLE: Preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment of inflammatory diseases.
INVENTOR(S): Morley, Andrew David; Poyser, Jeffrey Philip
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063185	A1	20040729	WO 2004-GB106	20040113
WO 2004063185	A8	20040923		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004203967	A1	20040729	AU 2004-203967	20040113
CA 2512336	A1	20040729	CA 2004-2512336	20040113
EP 1583756	A1	20051012	EP 2004-701632	20040113

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2004006774	A	20051227	BR 2004-6774	20040113
CN 1738812	A	20060222	CN 2004-80002304	20040113
JP 2006515355	T	20060525	JP 2006-500206	20040113
US 2006111431	A1	20060525	US 2005-542044	20050713
NO 2005003810	A	20051012	NO 2005-3810	20050812
PRIORITY APPLN. INFO.:			SE 2003-91	20030115
			WO 2004-GB106	20040113

AB Title compds. I [R1 = H, CH3; R2 = H, halo, CN, etc.; X = C(R4R5)yNR3(CR4R5)m-Ar; y = n + 1; n = 1-3; m = 0-3; R3 = H, (un)substitued alkenyl, alkyl; R4, R5 = H, alkyl with provisos; Ar = Ph ring or a 5- or 6- membered heterocyclic ring containing one to three heteroatoms, e.g., O, N, S;] and their pharmaceutically acceptable salts were prepared For example, Pd mediated coupling of 2-[(aminocarbonyl)amino]- 5-bromothiophene-3-carboxamide and bromide II, e.g., prepared from 1-bromo-2-[2-chloroethoxy]benzene and N-methylbenzylamine, afforded thiophenylcarboxamide III. In IKK-2 filter kinase inhibition assays, 6-examples of compds. I exhibited IC50 values ranging from 0.01-1.43 μM, e.g., the IC50 value of thiophenylcarboxamide III was 0.04 μM. Compds. I are claimed useful for the treatment of inflammatory diseases.

MSTR 1



G1 = 9



G4 = NH
G7 = 35



G10 = bond
G12 = Ph (opt. substd. by 1 or more G13)
G22 = 36



G24 = CH2CH2
G25 = NHCONH2
Patent location: claim 1
Note: additional ring formation also claimed
Note: also incorporates claim 7
Note: and pharmaceutically acceptable salts

Search History

```
L1              STRUCTURE UPLOADED
L2            0 SEA SSS SAM L1
L3           80 SEA SSS FUL L1

     FILE 'CAPLUS' ENTERED AT 13:45:51 ON 29 MAR 2007
L4            4 SEA ABB=ON  PLU=ON  L3
L5            4 SEA ABB=ON  PLU=ON  L4 AND PATENT/DT
L6            3 SEA ABB=ON  PLU=ON  L5 AND (PRY<=2004 OR AY<=2004 OR PY<=2004)


     FILE 'BEILSTEIN' ENTERED AT 13:48:25 ON 29 MAR 2007
L7            0 SEA ABB=ON  PLU=ON  L3
L8            0 SEA ABB=ON  PLU=ON  L3

     FILE 'MARPAT' ENTERED AT 14:13:15 ON 29 MAR 2007
L9              STRUCTURE UPLOADED
L10             STRUCTURE UPLOADED
L11           0 SEA SSS SAM L10
L12           2 SEA SSS FUL L10
L13           1 SEA ABB=ON  PLU=ON  L12/COM

     FILE 'CAPLUS' ENTERED AT 14:32:01 ON 29 MAR 2007
L14         173 SEA ABB=ON  PLU=ON  MORLEY A?/AU
L15          35 SEA ABB=ON  PLU=ON  POYSER J?/AU
L16           4 SEA ABB=ON  PLU=ON  L14 AND L15

L17           1 SEA ABB=ON  PLU=ON  L6 NOT L16

     FILE 'CAPLUS, MARPAT' ENTERED AT 14:35:44 ON 29 MAR 2007
L18           2 DUP REM L17 L13 (0 DUPLICATES REMOVED)
```